with a rating of 3.6 (4 is the best), which also suggests the stock is under stealth accumulation and likely to exceed 52 week high in the short term. DAKT is the best in class as the only full solution provider in the market. With a market value of $480 million, it can generate 95 cents a share in free cash flow, bringing its shares up to $16. Excellent entry point at $10.62, especially with an earnings beat tomorrow and positive guidance.
$12.25 is currently resistance, but in time it will become the long term floor. At present, JNJ doesn't want to be charged with manipulation and is "allowing" market forces to establish $12.25. As for the shorts, they're still make noise that JNJ is not strong enough to execute. JNJ has the firepower to make HCV their market., especially with covering all of ACHN's cost going forward. Relax and allow ACHN to work higher.
with Janssen responsible for all of the development costs and all subsequent costs related to commercialization of the HCV assets. Also, JNJ's investment to purchase 18.4 million shares at $12.25 is non-delutive at current price of ACHN. These two points makes the Seeking Alpha report less than honest, and apparently a "hidden agenda" piece. As for the truth, JNJ needs ACHN to make their HCV assets (valued at $2.7 billion) work. With Achillion's ACH-3102, JNJ has the only chance to gain meaningful assess (and huge profits) to the Hepatitis C market. At present ACHN's stock is under pressure because of a misunderstanding with the deal. Based on the SPM algorithm, in the near term ACHN stock is worth $18.00 and in the long term $31.00.
"True Float" is based on the probable shares that are in "public hands" with the ability to sell at any time. The balance of the outstanding shares are held by long term investors that are not inclined to liquidate on short term swings.